Drug Trial Radar · NCT07458061
Kamuvudine-9 (K9) in Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Feb 2026
Primary completion
Jun 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Dr. Bryan StrelowAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this investigation are to assess: 1. whether oral K9 is safe in subjects with DME, and 2. whether oral K9 improves BCVA compared to oral placebo
Conditions
- Diabetic Macular Edema
Interventions
Placebo Tablet: BIDDrug
Placebo tablets BID
Kamuvudine K9Drug
Kamuvudine K9
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v6.0Time frame: 4 weeks
- Change from baseline Best-Corrected Visual Acuity measured using the standardized ETDRS chartTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vistar Eye Center
Roanoke, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.